Darunavir, promising option in therapy multi-experience HIV-infected patients

Darunavir was approved in 2006 by the US FDA for patients harboring HIV-1 resistant to more then one protease inhibitor. It belongs to the second generation of protease inhibitors with potent activity against viral strains to all currently available protease inhibitors. Darunavir should always be co-administrated with low-dose ritonavir and with food. Current guidelines suggest that the goal of therapy in all HIV infected patients, including heavily experienced, is full viral suppression. Treatment options for patients infected with multidrug resistant HIV are limited. The results of clinical trials demonstrated that darunavir is effective and well tolerated. The POWER-1, 2, and 3 trials that used DRV/r showed that the compound had a potent effect in heavily pretreated patients. Ongoing studies in treatment-naïve and treatment-experienced will provide more data on the safety and efficacy of darunavir.